Population pharmacokinetics of mizoribine in pediatric patients with kidney disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical and Experimental Nephrology

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10157-015-1209-9PMID 26649561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mizoribine: A New Approach in the Treatment of Renal Disease

  2009cited by this paper
• Membrane transport mechanisms of mizoribine in the rat intestine and human epithelial LS180 cells.

  2009cited by this paper
• New equations to estimate GFR in children with CKD.

  2009cited by this paper
• Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study

  2008cited by this paper
• Mizoribine Treatment of Young Patients with Severe Lupus Nephritis: A Clinicopathologic Study by the Tohoku Pediatric Study Group

  2008cited by this paper
• Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers.

  2007cited by this paper
• Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy

  2007cited by this paper
• Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome.

  2007cited by this paper
• The nucleotide derivatives inosine and inosinic acid inhibit intestinal absorption of mizoribine in rats.

  2006cited by this paper
• Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis

  2006cited by this paper
• Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers.

  2006cited by this paper
• Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis.

  2005cited by this paper
• High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity

  2005cited by this paper
• Efficacy of Multidrug Therapy Combined with Mizoribine in Children with Diffuse IgA Nephropathy in Comparison with Multidrug Therapy without Mizoribine and with Methylprednisolone Pulse Therapy

  2004cited by this paper
• Mizoribine for the treatment of lupus nephritis in children and adolescents.

  2004cited by this paper
• Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis.

  2003cited by this paper
• Mizoribine: Mode of action and effects in clinical use

  2002cited by this paper
• Nephrotic syndrome and mizoribine in children

  2002cited by this paper
• A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome.

  2000cited by this paper
• Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis.

  1999cited by this paper
• Clinical pharmacokinetic study of mizoribine in renal transplantation patients.

  1996cited by this paper
• Simplified high-performance liquid chromatographic method for determination of mizoribine in human serum.

  1988cited by this paper

• Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients

  2020cites this paper
• Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)

  2018cites this paper
• The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease

  2017cites this paper
• Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome

  2016cites this paper
• Evaluation of Usefulness of Population Pharmacokinetic Analysis Considering Interindividual Variability of Bioavailability (2)

  2016cites this paper